Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Gliosarcoma 1Glioblastoma 1

Interventions

fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 4Rituximab 3Immunoglobulin G 3Everolimus 3Disulfides 3Cyclosporine 3pembrolizumab 2mogamulizumab 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2ProMune 2Photopheresis 2Mycophenolic Acid 2Methotrexate 2Lenalidomide 2Gene Expression Profiling 2Etoposide 2Cyclophosphamide 2Busulfan 2Bortezomib 2veliparib 1romidepsin 1navitoclax 1magrolimab 1liposomal doxorubicin 1indolepropanol phosphate 1flt3 ligand protein 1ethanolamine oleate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mycosis Fungoides × O(6)-benzylguanine × Clear all
NCT00961220 2018-05-22

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 6 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡